Coronavirus channel feed

What about No­vavax? Vac­cine com­pa­ny's boost­er is left out of FDA ac­tion on Pfiz­er, Mod­er­na shots

Last year

Bernie Sanders lifts hold on NIH nom­i­nee fol­low­ing Re­gen­eron price con­ces­sions

Last year
People

Mod­er­na touts broad­er an­ti­body da­ta on up­dat­ed Covid vac­cine as it gears up for fall roll­out

Last year
R&D

Bavar­i­an Nordic aban­dons Covid boost­er af­ter da­ta show it's not as ef­fec­tive against new vari­ants

Last year
R&D

Pfiz­er and BioN­Tech 'ready to ship' up­dat­ed Covid-19 vac­cine in EU on heels of CHMP rec­om­men­da­tion

Last year
Pharma

CEPI to in­vest up to $80M on ChA­dOx vac­cine plat­form, pre­vi­ous­ly used in As­traZeneca/Ox­ford Covid jab

Last year
Financing

WHO se­cures three li­cens­ing deals to boost Covid vac­cine and as­say prod­uct op­tions

Last year
Deals
Manufacturing

Drug­mak­ers pull back af­ter Covid boom, plan­ning to cut costs as they pre­pare for in­dus­try’s next era

Last year
R&D
Pharma

No­vavax plans to have up­dat­ed Covid vac­cine to mar­ket by Sep­tem­ber — but will it be ready in time?

Last year
Pharma

Born out of Omega push for pan­dem­ic treat­ments, Aeri­um Ther­a­peu­tics en­ters long Covid R&D

Last year
Startups
R&D

CSPC to launch Paxlovid ver­sion in Chi­na; SEC charges ex-Pfiz­er em­ploy­ee with in­sid­er trad­ing

Last year
China
Law

Eu­ro­pean Com­mis­sion so­lid­i­fies vac­cine man­u­fac­tur­ing plans to pre­pare for fu­ture health emer­gen­cies

Last year
Pharma

VRB­PAC unan­i­mous­ly rec­om­mends mono­va­lent, XBB lin­eage for next fal­l's Covid-19 vac­cine cam­paign

Last year
FDA+

FDA lays out what to ex­pect at ad­com­m's se­lec­tion of strains for Covid-19 vac­cine cam­paign this fall

Last year
FDA+

Eu­ro­pean Com­mis­sion to re­ceive few­er Pfiz­er-BioN­Tech vac­cine dos­es un­der amend­ed con­tract

Last year
Pharma

More than a year af­ter its emer­gency au­tho­riza­tion, FDA ful­ly ap­proves Pfiz­er's Covid pill Paxlovid for adults

Last year
FDA+

No­vavax lays off hun­dreds of em­ploy­ees as new CEO goes in­to res­cue mode

3 years ago
People

Enan­ta is look­ing for a part­ner on its Covid pill af­ter a PhII study dis­ap­points

3 years ago

Covid-19 pub­lic health emer­gen­cies are end­ing. What's chang­ing?

3 years ago
Pharma

Covid drug and vac­cine sales nose­dive, dent­ing bio­phar­ma rev­enue across the board

3 years ago
Pharma

For­mer Covid test­ing czar dish­es on the pol­i­tics that in­ter­rupt­ed the ear­ly pan­dem­ic re­sponse

3 years ago

South Dako­ta-based Covid-19 trans­genic cow an­ti­body start­up claims its first PhI­II win

3 years ago
R&D

FDA sim­pli­fies Covid-19 bi­va­lent vac­ci­na­tion process ahead of June ad­comm

3 years ago
Pharma
FDA+

In­flaRx wins FDA emer­gency use au­tho­riza­tion for Covid an­ti­body

3 years ago
Pharma
FDA+
First page Previous page 123456 Next page Last page
A service from the Financial Times